Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Rademaker-Lakhai, C. Terret, S. Howell, C. Baud, R. Boer, D. Pluim, J. Beijnen, J. Schellens, J. Droz (2004)
A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid TumorsClinical Cancer Research, 10
J. Singer (2005)
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.Journal of controlled release : official journal of the Controlled Release Society, 109 1-3
Chun Li, R. Newman, Qingping Wu, S. Ke, Wei Chen, T. Hutto, Z. Kan, M. Brannan, C. Charnsangavej, S. Wallace (2000)
Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumorCancer Chemotherapy and Pharmacology, 46
A. Sparreboom, O. Tellingen, W. Nooijen, J. Beijnen (1996)
Tissue distribution, metabolism and excretion of paclitaxel in miceAnti-Cancer Drugs, 7
D. Kohler, B. Goldspiel (1994)
Paclitaxel (Taxol)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 14
S. Longnecker, R. Donehower, A. Cates, T. Chen, R. Brundrett, L. Grochow, D. Ettinger, M. Colvin (1987)
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.Cancer treatment reports, 71 1
L. Paz-Ares, H. Ross, M. O'brien, A. Rivière, U. Gatzemeier, J. Pawel, E. Kaukel, L. Freitag, W. Digel, H. Bischoff, R. García-Campelo, N. Iannotti, P. Reiterer, I. Bover, J. Prendiville, A. Eisenfeld, F. Oldham, B. Bandstra, J. Singer, P. Bonomi (2008)
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancerBritish Journal of Cancer, 98
H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom (2001)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.European journal of cancer, 37 13
Chun Li, D. Yu, R. Newman, F. Cabral, L. Stephens, N. Hunter, L. Milas, S. Wallace (1998)
Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.Cancer research, 58 11
Xinjian Lin, Q. Zhang, J. Rice, D. Stewart, D. Nowotnik, Stephen Howell (2004)
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models.European journal of cancer, 40 2
P. Vasey, S. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. Thomson, L. Murray, T. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy (1999)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer ConjugatesClinical Cancer Research, 5
A. Sparreboom, C. Scripture, V. Trieu, Paul Williams, T. De, Andrew Yang, Bridget Beals, W. Figg, M. Hawkins, N. Desai (2005)
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)Clinical Cancer Research, 11
V. Omelyanenko, C. Gentry, P. Kopečková, J. Kopeček (1998)
HPMA copolymer–anticancer drug–OV‐TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitroInternational Journal of Cancer, 75
Chun Li, S. Ke, Q. Wu, W. Tansey, N. Hunter, L. Buchmiller, L. Milas, C. Charnsangavej, S. Wallace (2000)
Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 7
D. Richards, P. Richards, D. Bodkin, M. Neubauer, F. Oldham (2005)
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.Clinical lung cancer, 7 3
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, John Brown, W. Peters, A. Jacobs, A. Mehdi, S. Rivkin, A. Eisenfeld, D. Spriggs (2004)
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 22
M. O'Brien, M. Socinski, A. Popovich, I. Bondarenko, A. Tomova, Borys Bilynsky˘ı, Y. Hotko, V. Ganul, Ippolit Kostinsky, A. Eisenfeld, L. Sandalic, F. Oldham, B. Bandstra, A. Sandler, J. Singer (2008)
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 3
E. Briasoulis, V. Karavasilis, E. Tzamakou, D. Rammou, Kali Soulti, C. Piperidou, N. Pavlidis (2004)
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxelCancer Chemotherapy and Pharmacology, 53
N. Lin, L. Parker, S. Come, H. Burstein, Margaret Haldoupis, N. Ryabin, R. Gelman, E. Winer, L. Shulman (2007)
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactionsInvestigational New Drugs, 25
S. Kim, Jaewon Yu, Jang‐Won Lee, E. Park, S. Chi (2005)
Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution.Journal of pharmaceutical and biomedical analysis, 39 1-2
P. Calvo, B. Gouritin, H. Chacun, D. Desmaële, J. D'angelo, J. Noel, D. Georgin, E. Fattal, J. Andreux, P. Couvreur (2001)
Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain DeliveryPharmaceutical Research, 18
H. Maeda, L. Seymour, Y. Miyamoto (1992)
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.Bioconjugate chemistry, 3 5
E. Rowinsky, R. Donehower (1995)
Drug therapy : paclitaxel (Taxol)The New England Journal of Medicine, 332
J. Singer, S. Shaffer, B. Baker, A. Bernareggi, S. Stromatt, Drew Nienstedt, M. Besman (2005)
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxaneAnti-Cancer Drugs, 16
J Thorac Oncol
J Kopecek (1991)
Targetable polymeric anticancer drugs Temporal control of drug activityAnn N Y Acad Sci, 618
J. Rice, J. Gerberich, D. Nowotnik, S. Howell (2006)
Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-Platinum Tumor-Targeting Drug Delivery SystemClinical Cancer Research, 12
H. Bardelmeijer, Ingrid Oomen, M. Hillebrand, J. Beijnen, J. Schellens, O. Tellingen (2003)
Metabolism of paclitaxel in miceAnti-Cancer Drugs, 14
J. Kopeček (1991)
Targetable Polymeric Anticancer DrugsAnnals of the New York Academy of Sciences, 618
C. Langer, K. O'Byrne, M. Socinski, S. Mikhailov, K. Leśniewski-Kmak, M. Šmakal, T. Ciuleanu, S. Orlov, M. Dediu, D. Heigener, A. Eisenfeld, L. Sandalic, F. Oldham, J. Singer, H. Ross (2008)
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 3
P. Vasey, S. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. Thomson, L. Murray, T. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy (1999)
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 1
Amarnath Sharma, E. Mayhew, R. Straubinger (1993)
Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model.Cancer research, 53 24
(2010)
Cancer Chemother Pharmacol
Milly Jonge, H. Bongard, A. Huitema, R. Mathôt, H. Rosing, P. Baas, N. Zandwijk, J. Beijnen, J. Schellens (2004)
Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung CancerClinical Cancer Research, 10
J. Singer, B. Baker, P. Vries, Anil Kumar, S. Shaffer, E. Vawter, M. Bolton, P. Garzone (2003)
Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.Advances in experimental medicine and biology, 519
Incorporation of PTX into the PGG–PTX polymer significantly prolonged the half-life of total taxanes, extractable taxane, and native PTX in both the plasma and tumor compartments. This resulted in a large increase in the amount of active PTX delivered to the tumor. PGG–PTX is an attractive candidate for further development.
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Feb 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.